

## Research Article

# Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects against *Bordetella pertussis* Infection

Noelia Olivera,<sup>1</sup> Celina E. Castuma,<sup>1</sup> Daniela Hozbor,<sup>1</sup> María E. Gaillard,<sup>1</sup>  
Martín Rumbo,<sup>2</sup> and Ricardo M. Gómez<sup>1</sup>

<sup>1</sup> Instituto de Biotecnología y Biología Molecular, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CCT-La Plata, CONICET-UNLP, Calle 49 y 115, 1900 La Plata, Argentina

<sup>2</sup> LISIN, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calle 48 y 115, 1900 La Plata, Argentina

Correspondence should be addressed to Ricardo M. Gómez; [rmg1426@gmail.com](mailto:rmg1426@gmail.com)

Received 1 March 2014; Revised 14 April 2014; Accepted 22 April 2014; Published 13 May 2014

Academic Editor: Ana Lucia Nascimento

Copyright © 2014 Noelia Olivera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study examined the immunogenic properties of the fusion protein fimbria 2 of *Bordetella pertussis* (Fim2)—cholera toxin B subunit (CTB) in the intranasal murine model of infection. To this end *B. pertussis* Fim2 coding sequence was cloned downstream of the cholera toxin B subunit coding sequence. The expression and assembly of the fusion protein into pentameric structures (CTB-Fim2) were evaluated by SDS-PAGE and monosialotetrahexosylganglioside (GM1-ganglioside) enzyme-linked immunosorbent assay (ELISA). To evaluate the protective capacity of CTB-Fim2, an intraperitoneal or intranasal mouse immunization schedule was performed with 50 µg of CTB-Fim2. Recombinant (rFim2) or purified (BpFim2) Fim2, CTB, and phosphate-buffered saline (PBS) were used as controls. The results showed that mice immunized with BpFim2 or CTB-Fim2 intraperitoneally or intranasally presented a significant reduction in bacterial lung counts compared to control groups ( $P < 0.01$  or  $P < 0.001$ , resp.). Moreover, intranasal immunization with CTB-Fim2 induced significant levels of Fim2-specific IgG in serum and bronchoalveolar lavage (BAL) and Fim2-specific IgA in BAL. Analysis of IgG isotypes and cytokines mRNA levels showed that CTB-Fim2 results in a mixed Th1/Th2 (T-helper) response. The data presented here provide support for CTB-Fim2 as a promising recombinant antigen against *Bordetella pertussis* infection.

## 1. Introduction

Pertussis or whooping cough is an acute respiratory disease whose principal etiological agent is the gram-negative bacterium *Bordetella pertussis* [1]. The clinical manifestations are more severe in infants than in adolescents or adults, who are now recognized as the main source of infection [2]. The best way to prevent pertussis is vaccination with either whole cellular (wP) or acellular (aP) vaccines [3]. Protective immunity generated by wP appears to be mediated largely by Th1 cells, whereas less efficacious alum-adjuvanted aP induce strong antibody Th2 responses [4].

Despite widespread pertussis immunization in childhood for more than 50 years, pertussis is considered to be the most poorly controlled bacterial vaccine-preventable disease [5] and remains an endemic disease with regular epidemics

[6]. Currently, there are an estimated 16 million cases and 195,000 deaths due to pertussis globally each year, most of them in developing countries [1]. The most vulnerable to the disease correspond to groups of unvaccinated infants, partially vaccinated children, and persons who have completed the immunization schedule with waning immunity [1]. In addition, since the early 1980s there has been an increase in reported cases of pertussis [5], even in countries with a high vaccination coverage rate [7]. Waning immunity conferred by vaccines, increased recognition, changes in diagnostic testing and reporting, and adaptation of the agent to immunity induced by vaccines are some of the factors that may have contributed to this increase [5].

Taken together, it is clear that additional vaccine approaches are needed. Some of the new approaches under trial include vaccination of newborns and additional booster

doses for older adolescents and adults. Innovative vaccines are also being studied [1]. In this regard, since infection by *B. pertussis* is usually restricted to the airways, an interesting alternative may be mucosal vaccination [8, 9]. It has been shown that mucosal vaccination is the best way to achieve a strong cellular and humoral immune response in airways as well as systemically [10]. There are also important logistic reasons that have made mucosal immunization attractive for public health use. Mucosal vaccines should be easier and cheaper to administer than parenteral vaccines and also have a lower risk of transmitting hepatitis B virus and HIV infections [11].

However, most protein antigens are poorly immunogenic and potent adjuvants are often needed to enhance immunity [12]. The cholera toxin B subunit (CTB) is among the most potent mucosal adjuvants known [13, 14]. CTB is the pentameric nontoxic portion of cholera toxin (CT) responsible for the binding of the holotoxin to the monosialotetrahexosylganglioside (GM1 ganglioside) receptor [15]. Chemical and genetic conjugations of CTB with different heterologous antigens from simian immunodeficiency virus and *Schistosoma mansoni*, among others, have shown promising results [16, 17].

The fimbriae (Fim) proteins are promising as immunogens to be used by the mucosal route because they act as pathogen-associated molecular patterns (PAMPs) [18, 19] and, in the case of Fim2 and 3 of *B. pertussis*, have known immunogenic properties and although Fim3 seems to exhibit lower protective capacity than Fim2 when isolated from *B. pertussis*, both have justified their presence in most recent acellular vaccines [20, 21].

In this study, we constructed a histidine-tagged CTB-Fim2 fusion protein in order to evaluate its protective capacity and immunogenic properties in a *B. pertussis* respiratory infection murine model. The results presented here showed that CTB-Fim2 is a promising antigen against *B. pertussis* infection.

## 2. Materials and Methods

**2.1. Strain and Growth Conditions.** The *Escherichia coli* strain DH5 $\alpha$  (Invitrogen, USA) was used for all routine cloning experiments, whereas the BL21(SI) and BL21Star (DE3) *E. coli* competent cells (Invitrogen) were used for recombinant protein expression. The *B. pertussis* strain used in this study was Tohama phase I [22–24] obtained from the Pasteur Institute, Paris, France. The strain from glycerol stock was cultured on Bordet-Gengou agar (BGA, Difco) supplemented with 1% glycerol and 10% (v/v) defibrinated sheep blood and incubated at 36°C for 3 days. The bacteria was then replated in the same medium for 24 h and the subcultures were grown in Stainer-Scholte liquid medium (SS) [25], with shaking at 36°C for 20 h.

**2.2. Cloning of Recombinant Proteins.** The *fim2* (621 bp) gene, from *B. pertussis* strain Tohama phase I, was amplified from genomic DNA by PCR. The mixture was subjected

to a program consisting of a DNA denaturation step at 94°C for 2 min, 35 cycles at 94°C for 15 s, 48°C for 15 s, and 72°C for 40 s. The following oligonucleotides were used for cloning into pET-TOPO 200 and pAectxB plasmids, respectively: Fim2F 5' CACCATGCCATGATCTCG3' and Fim2R 5' TTCGCTCCTGCATGGAATAC3'; CTBFim2F 5' TGGTTACGCGTATGTTACCCATGCAAATCCC3' and CTBFim2R 5' CTGATAAGCTTCTAGGGGTAGACCA CGG3'. In bold are the *Mlu*I and *Hind*III restriction sites, respectively. The amplified products were cloned into pET-TOPO 200 vector and transferred to pDEST17 according to the manufacturer's instructions (Invitrogen) or into pAE-ctxB [26] using the *Mlu*I and *Hind*III sites in order to generate the pDEST17-*fim2* and pAE-*ctxB-fim2* plasmids. The recombinant clones were confirmed by PCR and sequenced.

### 2.3. Expression and Purification of the Recombinant Proteins.

The expression and purification of rFIM2 and CTB-Fim2 was performed as previously described for other recombinant proteins [27, 28]. Briefly, BL21(SI) *E. coli* competent cells were transformed with the pDEST17-*fim2* or pAE-*ctxB-fim2* plasmids and grown overnight (ON) at 37°C. Ampicillin-resistant colonies were inoculated in 5 mL on Luria Bertani (LB) medium with ampicillin (50  $\mu$ g/mL) without NaCl and grown ON at 37°C. On the following day, cultures were diluted 50-fold in LB-amp without NaCl and grown until A<sub>600</sub> reached 0.8, when NaCl was added to the medium at a final concentration of 300 mM. After 3 h, cells were collected by centrifugation, resuspended in 10 mL lysis buffer, pH 8.0 (Tris-Cl 20 mM and NaCl 100 mM), and lysed by sonication. Cellular lysates were centrifuged at 14,000 rpm for 30 min. Both recombinant proteins were recovered from the inclusion bodies and solubilized with 10 mL of solubilization buffer (8 M urea, 50 mM Tris-Cl, 500 mM NaCl, pH 8.0). The material was then dialyzed against 2 L of refolding buffer (500 mM NaCl, 50 mM Tris-Cl, pH 8.0). Refolded protein solution was adsorbed to the Ni<sup>2+</sup>-NTA resin (Invitrogen) and washed with ten volumes of binding buffer (100 mM NaCl, 20 mM Tris-Cl, pH 8.0) containing 5, 20, 40, and 60 mM imidazole. The proteins were eluted with five volumes of the same solution containing 250 mM imidazole. Fractions were analyzed by 10% SDS-PAGE. The purified proteins were dialyzed in one step. The equilibrium was established using 2 L of a 10 mM Tris-Cl, pH 8.0, 20 mM NaCl, and 0.1% (m/v) glycine solution. The identity of the expressed protein and its molecular weight were confirmed by MALDI-TOF mass spectrometry. Searches for and the identification of peptides were performed using a licensed version of MASCOT software (Matrix Science) with a peptide tolerance of 50 ppm. Monoisotopic peptide masses were used to search the database, allowing a molecular mass range for 2-DE analyses of 15%. Purified CTB was purchased from Sigma (Argentina). For immunogenicity studies, contaminant LPS was removed from aliquots of recombinant proteins using the Detoxi-Gel Endotoxin Removing Gel columns (Thermo Scientific-Pierce, USA), according to the manufacturer's

instructions. The purification of BpFim2 was similar to a procedure described elsewhere [29].

**2.4. *Limulus Amebocyte Lysate Assay (LAL Test).*** The chromogenic LAL assay for endotoxin activity of the protein samples was performed using the QCL-1000 kit (Bio-Whittaker, MD), according to the manufacturer's instructions. In all cases, the final LPS content was less than  $5 \times 10^{-6}$   $\mu\text{g}/\text{mL}$ .

**2.5. *Immunoblotting.*** The immunoblot analysis (IB) was performed as previously described [28]. Briefly, aliquots were subjected to SDS-PAGE and then transferred to nitrocellulose membranes (GE Healthcare). Membranes were blocked with 5% nonfat dried milk in PBS containing 0.05% Tween 20 (PBS-T) and then incubated with a mouse antiserum (1:2500) against CTB in 5% nonfat dried milk/PBS-T for 2 h at RT. After washing, the membrane was incubated with HRP-conjugated anti-mouse IgG (1:5000; Sigma) in 5% nonfat dried milk/PBS-T for 1 h. The bands were revealed with ECL reagent kit chemiluminescence substrate (GE Healthcare).

**2.6. *Pentamer Analysis Assays.*** To determine whether CTB-Fim2 folds into pentamers during SDS-PAGE, samples were subjected to denaturing and nondenaturing conditions. In the latter case, samples were not boiled, and the sample buffer used did not contain  $\beta$ -mercaptoethanol. The ability of the CTB pentamers to bind to their cellular receptor was assessed using a GM1-ELISA assay. This protocol was adapted from a previously published study [28]. Briefly, 96-well plates (Nunc) were coated with 0.5  $\mu\text{g}$  per well (100  $\mu\text{L}$ ) of GM1 (Sigma) in PBS, pH 7.4 at 4°C for 16 h. As a negative control, the wells were coated with bovine serum albumin (BSA) at the same concentration (5  $\mu\text{g}/\text{mL}$ ) in PBS pH 7.4. Commercial CTB was used as a positive control. Plates were blocked and then washed five times. Afterwards, the wells were incubated with 100  $\mu\text{L}$  of the recombinant protein serially diluted in PBS 1/2 from ~300 nM to 146 pM for 2 h at 37°C and then washed. Microtiter plates were incubated for 1 h at 37°C with a 1/2500 dilution of a polyclonal anti-CTB serum [28] in 5% nonfat dried milk/PBS-T and washed. Thereafter, they were incubated with the anti-mouse conjugated to HRP (Santa Cruz Biotechnology, USA) diluted 1/4000 for 1 h at 37°C. After washing, plates were revealed by the addition of 10 mg o-phenylenediamine (OPD) in 10 mL of a 0.2 M citrate-phosphate buffer, pH 5.0, in the presence of 10  $\mu\text{L}$  of  $\text{H}_2\text{O}_2$ . The reaction was stopped by the addition of 4 M  $\text{H}_2\text{SO}_4$ . The absorbance was measured at 492 nm in all cases.

**2.7. *Immunization of Mice and Sample Collection.*** Groups of 4–8 and 3–4 week-old female BALB/c mice (Instituto Biológico Argentino, Argentina) received 50  $\mu\text{g}$  of purified CTB-Fim2 intraperitoneal or intranasally in 50  $\mu\text{L}$  of PBS on days 0, 12, and 24 with aluminum hydroxide as an adjuvant (0.2 mg/mL, IP) or without external adjuvant (IN). Mice immunized with CTB (5  $\mu\text{g}$ , IN only), rFim2, or BpFim2

alone (50  $\mu\text{g}$ ) and mice inoculated with 50  $\mu\text{L}$  of PBS were used as control groups.

Blood samples were obtained from a facial vein at days 12, 24, and 36, and the obtained sera were stored at  $-20^\circ\text{C}$ . BAL fluid was collected postmortem after the challenge by flushing the lungs twice with PBS. An incision was made in the neck, so as to expose the trachea. Using a 5 mL syringe, 1 mL of PBS was slowly introduced into the lungs via the trachea and then syringed out. This was repeated twice. The protease inhibitor phenylmethylsulfonyl fluoride (Sigma) was added to each sample at a concentration of 1 mM following collection, and samples were kept at  $-20^\circ\text{C}$  until use. At least two independent experiments were performed with consistent results.

**2.8. *Antibody Determination by ELISA.*** Ninety-six well plates were coated with 5  $\mu\text{g}/\text{mL}^{-1}$  of rFim2/well in carbonate-bicarbonate buffer, pH 9.6 at 4°C ON. The plates were washed three times with PBS-T. Nonspecific binding was reduced by blocking the plates with 300  $\mu\text{L}/\text{well}$  of 5% nonfat milk/PBS-T (m/V) at 37°C for 1 h. The plates were washed three times with PBS-T. Samples that were to be tested for Fim2-specific antibodies were diluted 1/20 for sera IgG, IgG1, IgG2a, and IgA (the mucosal fluids were not previously diluted) in PBS-T, with 50  $\mu\text{L}$  being added to the plate in duplicate and serially diluted 2-fold down the plate. A final 1/64 dilution was used for comparison and graphical purposes. The plates were incubated at 37°C for 1 h and then washed three times with PBS-T. Bound antibodies were detected using at appropriate dilutions commercial peroxidase conjugated anti-mouse, IgG, IgG1a, IgG2, and IgA (Santa Cruz Biotechnology). The subsequent steps were performed as described in GM1-ELISA.

**2.9. *Protection Assay in a Mouse Respiratory Model.*** The challenge assay was performed using the mouse respiratory model of *B. pertussis* infection as described previously [30]. Briefly, cohorts of BALB/c mice were immunized as described above, and 12 days after the last dose of immunization, they were challenged with a suspension of  $5 \times 10^7$  CFU of virulent *B. pertussis* in 50  $\mu\text{L}$  of PBS. Inoculation was performed by pipetting the inoculum into the nostrils. Animals were euthanized by  $\text{CO}_2$  overdose 8 days postinfection (PI), and the lungs were excised. Left lung was used for bacterial recovery as described previously [30], and the right lung was split in two samples, one used for cytokine level and the other for routine histological examination.

All animal experiments were performed according to our Institute's Ethical Committee and the National Institutes of Health guidelines [31].

**2.10. *RNA Isolation and RT-PCR.*** Total RNA was isolated from lung tissue by mechanical homogenization in Trizol reagent (Invitrogen, Argentina), as recommended by the manufacturer. DNase treatment was performed with an

RNase-free DNase Kit (Qiagen, Germany). cDNA was synthesized from 500 ng of total RNA with 15 mM of random hexamers and SuperScript III reverse transcriptase (Invitrogen, Argentina), according to the manufacturer's instructions.

**2.11. Real-Time PCR.** All q-PCR studies were performed with a Line-Gene instrument (Bioer Technology, China). The TAQurate green real-time PCR MasterMix (Epicentre Biotechnologies) was used for all reactions, following the manufacturer's instructions. Initial denaturation was carried out at 94°C for 10 min, followed by 65 cycles of 20 s at 94°C, 15 s at the respective annealing temperatures and 15 s at 72°C each, and a final extension at 72°C for 2 min. A melting curve analysis was performed immediately after amplification at a linear temperature transition rate of 0.3°C/s from 70°C to 89°C with continuous fluorescence acquisition. The size of all PCR products was confirmed by agarose gel electrophoresis. Transcription levels of IL-4 (F 5'CATCGGCATTTTGAACGAGGTCA3'; R 5'CTTATC-GATGAATCCAGGCATCG3'); and IFN- $\gamma$  (F 5'CTTGGA-TATCTGGAGGAAGTGGC3'; R 5'GCGCTGACCTGT-GGGTTGTTGA3') were measured in all samples and normalized to  $\beta$ -actin levels (F 5'GCTTCTTTGCAGCTC-CTTCGT3'; R 5'CATTTCATGTTTCGAATCATTTCAAA3').

**2.12. Statistical Analysis.** A one-way ANOVA test was used to determine significant differences in the assays, and data are expressed as mean  $\pm$  SEM. When necessary, data were analyzed by one-way analysis of variance followed by the Bonferroni multiple comparison test to determine significant differences between groups.  $P < 0.05$  was considered statistically significant.

### 3. Results

**3.1. Expression and Purification of CTB-Fim2.** The design used to construct the recombinant plasmid is illustrated in Figure 1(a). The fusion protein was expressed and purified as described previously [28]. The results are shown in Figures 1(b) and 1(c), respectively. As expected, the molecular weight of CTB-Fim2 was 36 kDa. The presence of CTB in the fusion protein was confirmed by immunoblotting using a murine anti-CTB antiserum (Figure 1(d)) and by MALDI-TOF mass spectrometry. While a positive result was detected for CTB-Fim2, no band was detected in the nontransformed *E. coli* extract or when the primary antibody was omitted (data not shown). These data demonstrated that the recombinant *E. coli* harboring the plasmid express the recombinant protein recognizable by anti-CTB antibodies.

**3.2. Pentamer Conformation of CTB-Fim2.** The oligomeric structure of CTB-Fim2 was analyzed by gel electrophoresis. Figure 2(a) (lane 1) shows that CTB-Fim2, previously solubilized in denaturing Laemmli sample buffer and boiled, migrated with a MW of 36 kDa. In contrast, when protein was solubilized in nondenaturing Laemmli sample buffer without boiling (lane 2) it migrated with a MW of 180 kDa. These




FIGURE 1: Immunogen design, expression, purification, and immunoblot analysis of the CTB-Fim2 fusion protein. (a) Schematic representation of immunogen design. (b) Protein expression and purification in the *E. coli* (SI) strain transformed with pAE-CTB-Fim2. Protein expression was assayed using a 10% SDS-PAGE gel and shows a 36 kDa band. (c) Analysis of the recombinant CTB-Fim2 protein after elution from Ni<sup>2+</sup>-charged beads with 250 mM imidazole. (d) Reactive protein bands probed with a mouse antiserum (1:2500) against CTB. NI and I stand for noninduced and induced bacterial extract, respectively.

results suggest that native CTB has a pentameric structure after the refolding process.

The pentameric conformation was also evaluated by its ability to bind to its receptor GM1-ganglioside in an ELISA assay since monomeric CTB has a low affinity for GM1 [32]. For detection, anti-CTB serum was used (Figure 2(b)). The results showed that commercial CTB and purified CTB-Fim2 were similarly able to bind GM1 in a concentration-specific manner. These results strongly suggest that CTB-Fim2 has a pentameric structure and indicate that the presence of Fim2 does not abrogate either the formation of the pentamer or binding to its GM1 receptor.

**3.3. Protective Capacity of CTB-Fim2.** To evaluate the protective capacity against *B. pertussis* infection of CTB-Fim2 immunization, we employed a previously described mice model [30]. Balb/c mice were immunized intraperitoneally or intranasally three times with (50  $\mu$ g/dose) the recombinant CTB-Fim2, rFim2, and BpFim2 and were challenged with a  $5 \cdot 10^7$  CFU of virulent *B. pertussis* Tohama phase I strain/50  $\mu$ L suspension in PBS 12 days following the last dose. Mice treated with CTB (5  $\mu$ g, IN only) or 50  $\mu$ L of PBS were used as negative controls.

The results obtained at 8 days after the challenge showed a significant reduction in bacterial counts in mice immunized either by the intraperitoneal or the intranasal route with CTB-Fim2 compared to the controls treated with PBS or CTB (IP  $3.7 \pm 0.2$  versus  $5.3 \pm 0.2$  logs CFU/lung,  $P < 0.01$ ) or (IN  $3.2 \pm 0.2$  versus  $4.9 \pm 0.1$  logs CFU/lung,  $P < 0.001$ ), respectively. In contrast, intraperitoneal or intranasal immunization with rFim2 did not significantly reduce the bacterial counts in lungs compared to control groups ( $4.8 \pm 0.1$  and  $5.3 \pm 0.1$




FIGURE 2: Pentamer formation of CTB-Fim2. (a) SDS-PAGE with purified CTB-Fim2. Lane 1 is the sample boiled in reducing conditions while lane 2 is the same protein sample not subjected to boiling and in nonreducing conditions. Bands of 36 and 180 kDa of CTB-Fim2 are shown, respectively. (b) GM1-ELISA to verify the ability of the pentamer to bind GM1-ganglioside using recombinant CTB-Fim2. Commercial CTB was used as a positive control. The 96-well plates were coated with GM1 or BSA and mouse anti-CTB antisera (1:2500).

logs CFU/lung, resp.). As expected, a significant decrease was seen between BpFim2, isolated from *B. pertussis* and used as a positive control, and control groups either by the intraperitoneal or the intranasal route ( $P < 0.001$ ) (Figure 3).

There were no statistically significant differences between mice immunized intraperitoneally or intranasally with CTB-Fim2 ( $3.7 \pm 0.2$  versus  $3.2 \pm 0.2$  CFU/lung).

These results indicate that intraperitoneal or intranasal administration of CTB-Fim2 was effective in protecting mice against intranasal challenge with *B. pertussis* with a dose of  $50 \mu\text{g}$  of immunogen. Moreover, CTB improved the protective capacity of rFim2 when it was genetically fused to the antigen.

**3.4. Serum IgG Levels Following Immunization.** To further characterize the immunogenic properties of CTB-Fim2, we

study the humoral response induced in serum samples collected during the intraperitoneal or intranasal immunization protocols, by ELISA. As expected, the specific humoral response increased after each immunization in all groups. To simplify the analysis, only the values of serum IgG at day 35, one day before challenge with *B. pertussis*, are shown (Figure 4). Either intraperitoneal or intranasal immunization with rFim2 or CTB-Fim2 generated a specific serum IgG response (DO at 492 nm = 0.9 and 0.6, resp., for rFim2; 0.9 or 1.2 for CTB-Fim2, resp.;  $P < 0.01$  and 0.001, resp.) (see Figure 4). These results show that meanwhile rFim2 and CTB-Fim2 generated similar levels of anti-Fim2 serum IgG after intraperitoneal immunization, the level of anti-Fim2 serum IgG elicited by CTB-Fim2 after intranasal immunization was significantly higher.

**3.5. Humoral Response in BAL Washes.** To assess the immune responses at the mucosal surface, groups of mice were immunized intranasally or intraperitoneally three times with PBS, CTB, rFim2, or CTB-Fim2 every 12 days followed by intranasal challenge with *B. pertussis* Tohama phase I strain ( $5 \times 10^7$  CFU/mouse). At 8 days postinfection animals were euthanized and BAL washes were collected for determination of anti-Fim2 IgG (a) and IgA (b) antibodies (Figure 5). Antibody levels were assayed using ELISA. Values represent the OD at 492 nm and are representative of two separate experiments ( $*P < 0.05$  versus CTB-Fim2 IP,  $**P < 0.001$  and  $***P < 0.0001$  versus PBS, CTB, and rFim2 IN,  $^{\circ}P < 0.05$  versus PBS and CTB,  $^+P < 0.05$  versus PBS, CTB, and rFim2 IN and IP, and  $^{++}P < 0.001$  versus CTB-Fim2 IP).

These results mainly indicate that rFim2, when administered intranasally, was not capable of generating a strong humoral response in BAL, but when CTB was genetically fused to the antigen, specific antibody levels significantly increased in BAL, giving high titers of IgG and IgA with the fusion protein.

**3.6. Analysis of Th Cell Response.** To gain partial insight into the nature of immune responses induced by intranasal immunization with CTB-Fim2, we first quantified serum IgG subtypes G1 and G2a specific to Fim2 at day 36 postimmunization and before challenge (Figure 6). In agreement with specific total IgG response values found in serum, significantly higher levels of IgG1 antibodies were detected in the rFIM2 and CTB-Fim2 groups compared with the negative controls (DO at 492 nm = IgG1: 1.1 and 1.3, resp.;  $P < 0.05$ ). In contrast, the IgG2a anti-Fim2 levels were only elevated by CTB-Fim2 (DO at 492 nm = IgG2a: 0.4 and 1.8, resp.,  $P < 0.01$ ). On the other hand, analysis of IFN- $\gamma$  and IL-4 mRNA levels (Figure 7) showed that meanwhile rFim2 and CTB-Fim2 induce an increase of IL-4, only CTB-Fim2 induces a significant increase of IFN- $\gamma$  in the lung of immunized mice compared with the negative controls. In addition, the histopathology analysis (Figure 8) showed a more intense inflammation in the lungs of mice immunized with CTB-Fim2 compared with the rFim2 and negative control groups. The enhanced inflammatory response detected at day 8 after




FIGURE 3: Protective capacity of CTB-Fim2. Groups of animals were immunized (a) intraperitoneally or (b) intranasally three times with PBS, CTB (IN only), rFim2, BpFim2, or CTB-Fim2 every 12 days followed by IN challenge with  $5 \times 10^7$  UFC of the Tohama I strain of *B. pertussis*. At 8 days postinfection, animals were killed and lung samples were collected for UFC counting. Each point represents the mean ( $\pm$  standard error) of 8 animals (\*\* $P < 0.001$  versus PBS; \*\*\* $P < 0.0001$  versus PBS, CTB, and rFim2).




FIGURE 4: Specific IgG antibodies in serum. Induction of serum anti-Fim2 IgG after intraperitoneal (a) or intranasal (b) immunization with PBS, CTB, rFim2, and CTB-Fim2. Anti-Fim2 IgG titers of individual serum collected immediately before challenge on day 36 are shown. Values represent the OD at 492 nm and show the mean ( $\pm$  standard error) of 8 animals (\*\* $P < 0.001$  versus rFim2 IN; \*\*\* $P < 0.0001$  versus PBS and CTB IN and IP).

the challenge was not deleterious for the animal evaluated as survival or presence of symptoms, including lethargy, hypothermia, or changes in nose/mucosal surfaces.

#### 4. Discussion

Natural infection with *B. pertussis* induces strong and long-lasting immunity that wanes later than vaccine-induced immunity [33]. The use of the mucosal route of vaccination is an attractive alternative to the use of the parenteral route since it may mimic many aspects of the immune response

elicited against the natural infection [34]. Moreover, a single nasal dose of a live attenuated *B. pertussis* was effective against whooping cough in the murine model [35]. In addition, other pertussis antigens such as pertactin and filamentous hemagglutinin or even the more complex component, the outer membrane vesicles administered via the mucosal route, has proven to be effective against *B. pertussis* infection [36, 37], showing that mucosal vaccination may constitute a possible alternative to the widely used parenteral route.

The presence of fimbriae (serotypes 2 and 3) in acellular pertussis vaccines has been shown to improve short-term vaccine efficacy in young children [38, 39]. In later studies, it was also described as a correlation between IgG anti-Fim2/3 and a reduced risk of disease [40, 41]. Although




FIGURE 5: Specific IgG and IgA antibodies in BAL washes. Groups of animals were immunized intranasally or intraperitoneally three times with PBS, CTB, rFim2, or CTB-Fim2 every 12 days followed by intranasal challenge with *B. pertussis* Tohama phase I strain of ( $5 \times 10^7$  CFU/mouse). At 8 days postinfection, animals were euthanized and BAL washes were collected to determine the levels of anti-Fim2 IgG (a) and IgA (b) antibodies. Antibody levels were assayed using ELISA. Values represent the OD at 492 nm and are representative of two separate experiments (\* $P < 0.05$  versus CTB-Fim2 IP, \*\* $P < 0.001$  and  $P < 0.0001$  versus PBS, CTB, and rFim2 IN, ° $P < 0.05$  versus PBS and CTB, + $P < 0.05$  versus PBS, CTB, and rFim2 IN and IP, and ++ $P < 0.001$  versus CTB-Fim2 IP).




FIGURE 6: IgG1 and IgG2a antibody isotype response. Comparison of the serum anti-Fim2 IgG1 and IgG2a levels induced by PBS, CTB, rFim2, or CTB-Fim2 via the intranasal (IN) route. Sera were collected from mice on day 36. The anti-Fim2 IgG1 and IgG2a titers were determined using ELISA. Data are expressed as the mean ( $\pm$ standard error) absorbance at 492 nm for each group. Statistical differences were observed in different comparisons (IgG1 CTB-Fim2 versus all other categories except rFim2 \*\*\* $P < 0.0001$ , rFim2 versus all other categories except CTB-Fim2 +++ $P < 0.0001$ , and IgG2a CTB-Fim2 versus all other categories °°° $P < 0.0001$ ).

it has been well established that Fim2 purified from *B. pertussis* confers protection against infection in the mouse respiratory model [20], mice intraperitoneal immunized with the recombinant protein (rFim2) are not protected against

challenge with *B. pertussis* [42]. The molecular basis of this difference has not been established, but it could be due to differences in the structure of Fim2 obtained from the two sources. Furthermore, the protective capacity of rFim2 delivered mucosally has not been reported previously.

Here we constructed CTB-Fim2 to explore Fim2 immunogenicity exploiting the adjuvant properties of the CTB molecule. CTB has been widely used as an adjuvant in rodent studies [13, 14]. When given via the oral or intranasal route, CTB not only elicits anti-CTB responses at multiple mucosal sites but also induces strong antibody responses to genetically fused administered antigens [32]. Previous studies have successfully tested the possibility of intranasal immunization with an acellular pertussis vaccine using CTB as an adjuvant, mixing recombinant CTB with pertussis toxoid and formalin-treated filamentous hemagglutinin [43]. Furthermore, a chimeric protein consisting of a divalent pertussis toxin (PTX) S1 fragment linked to the cholera toxin A2B fragment elicited protective immunity after three intranasal immunizations, showing the potent effect of CT as a mucosal adjuvant [44].

The CTB-Fim2 presented here formed a pentameric structure that seemed to be important in relation to its adjuvant capacity [13]. More importantly, a significant reduction in the number of bacteria recovered from the lungs was observed in mice immunized with CTB-Fim2 compared to those immunized with rFim2 or the control mice groups indicating that some antigen can offer protection when fused to CTB. The protective capacity of CTB-Fim2 over rFim2 may be due, at least in part, to both the increased uptake of coupled antigen across the mucosal barrier [45] and more efficient delivery to antigen-presenting cells [46]. In our




FIGURE 7: Cytokine mRNA expression levels in lung. Groups of animals were immunized intranasally three times with PBS, CTB, rFim2, or CTB-Fim2 every 12 days followed by intranasal challenge with  $5 \times 10^7$  UFC of the Tohama I strain of *B. pertussis*. At 8 days postinfection, animals were killed and lung samples were collected for measuring mRNA levels of IFN- $\gamma$  (a) and IL-4 (b). Statistical differences were observed between CTB-Fim2 and all other groups except rFim2 ( $P < 0.001$ ).




FIGURE 8: Representative lung sections of BALB/c mice after *B. pertussis* challenge. Mild lung inflammation in PBS (a) and CTB (b) immunized mice. Moderate lung inflammation in Fim2 immunized animals (c). More severe lung inflammation with extensive cell exudate and some consolidation (pneumonia) was observed in lungs of CTB-Fim2 immunized animals (d). Hematoxylin-eosin staining in all cases.  $\times 150$  magnifications.



conditions and in agreement with other authors [42], rFim2 alone was not a good immunogen to reduce bacterial burden in lungs when administered via either the intraperitoneal or the intranasal route.

We also observed that intranasal immunization with CTB-Fim2 induced similar levels of anti-Fim2 serum IgG to those of intraperitoneal immunization. Furthermore, intranasal immunization with CTB-Fim2 induced high levels of anti-Fim2 IgG in BAL, indicating that both CTB-Fim2 and intranasal administration of the immunogen are adequate to induce a strong IgG response in the lungs.

Since one of the hallmarks of mucosal immunity is the production of secretory IgA, which acts to prevent bacterial and viral infection, and since CTB is capable of inducing specific IgA [47–51] by synergism with MyD88-dependent TLR signals which selectively imprint a IgA-inducing capacity in nonmucosal DCs [52], we studied this immunoglobulin in CTB-Fim2-immunized mice and verified that mice administered CTB-Fim2 elicited specific Fim2-IgA in BAL. This result was not observed with the other treatments performed herein and is consistent with previously published data showing that parenteral administration is less effective than mucosal routes in inducing mucosal responses important for protection [53]. In transcutaneous and intranasal immunization with a *Chlamydia muridarum* antigen, higher levels of specific IgG were induced in serum and BAL, while only intranasal immunization induced specific IgA in BAL using CTB as an adjuvant [54]. It seems that CTB may directly cause B cells to enhance S-IgA production [55] and the IgA isotype switching through TGF- $\beta$ 1 [56].

In mice that were immunized by mucosal administration of CTB-Fim2, we observed a comparable rise of IgG1 and IL4 mRNA levels and enhanced IgG2a and IFN- $\gamma$  mRNA levels as well as an increased inflammatory cell exudate. The enhanced inflammatory response in vaccinated mice, in agreement with other studies [57], may represent an enhanced host response to clear the bacteria. Taken together, the results showed that rFim2 results mainly in a Th2 response, as observed with aP vaccines [4], and that when rFim2 is fused to CTB, results in a mixed Th1/Th2 response, consistent with similar observations reported by others [58, 59] and improving one of the shortcomings observed in aP vaccines [60].

## 5. Conclusions

In conclusion, the results presented herein show that CTB is a potent adjuvant that when fused to Fim2 enhances their immunogenicity, stimulating both systemic and mucosal immune responses resulting in a mixed Th1/Th2 T-helper response. Having in mind the concerns that arose by the intranasal use of CTB and its subsequent accumulation in the olfactory bulb of mice [61] and that some vaccines administered by the intranasal route have been associated with Bell's palsy in humans [62], the fact that CTB-Fim2 administered by the intraperitoneal route also offers protection, supports its value as a protective immunogen. In addition, open the possibility to be used by other routes, even

mucosal routes, as have been done with CTB fused to other antigens in preclinical studies [63] as well as in humans (CTB administered by mucosal way in healthy adult volunteers, trial NCT00820144, NIH, publication pending). Therefore, the genetic fusion of *ctb* and *fim2* genes provides a new promising antigen against *Bordetella pertussis* infection.

## Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

## Acknowledgments

This work was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) PICT 07-00642 and PICT 07-00028 (Ricardo M. Gómez) and PICT 07-00029 (Daniela Hozbor). Daniela Hozbor is a member of the Scientific Career of CICBA. María E. Gaillard, Martín Rumbo, and Ricardo M. Gómez are members of the Scientific Career of CONICET. Celina E. Castuma is a Professor from UNLP.

## References

- [1] R. Libster and K. M. Edwards, "Re-emergence of pertussis: what are the solutions?" *Expert Review of Vaccines*, vol. 11, pp. 1331–1346, 2012.
- [2] S. Mattoo and J. D. Cherry, "Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies," *Clinical Microbiology Reviews*, vol. 18, no. 2, pp. 326–382, 2005.
- [3] J. Bailey, "A cellular vaccines for preventing pertussis in children," *American Family Physician*, vol. 84, no. 5, p. 504, 2011.
- [4] R. Higgs, S. C. Higgins, P. J. Ross, and K. H. Mills, "Immunity to the respiratory pathogen *Bordetella pertussis*," *Mucosal Immunology*, vol. 5, pp. 485–500, 2012.
- [5] T. A. Clark and N. Bobo, "CDC update on pertussis surveillance and Tdap vaccine recommendations," *NASN School Nurse*, vol. 27, pp. 297–300, 2012.
- [6] A. Elomaa, A. Advani, D. Donnelly et al., "Strain variation among *Bordetella pertussis* isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years," *Journal of Clinical Microbiology*, vol. 43, no. 8, pp. 3681–3687, 2005.
- [7] A. Elomaa, A. Advani, D. Donnelly et al., "Population dynamics of *Bordetella pertussis* in Finland and Sweden, neighbouring countries with different vaccination histories," *Vaccine*, vol. 25, no. 5, pp. 918–926, 2007.
- [8] K. Chen and A. Cerutti, "Vaccination strategies to promote mucosal antibody responses," *Immunity*, vol. 33, no. 4, pp. 479–491, 2010.
- [9] J. Holmgren and C. Czerkinsky, "Mucosal immunity and vaccines," *Nature Medicine*, vol. 11, no. 4, pp. S45–S53, 2005.
- [10] M. T. de Magistris, "Mucosal delivery of vaccine antigens and its advantages in pediatrics," *Advanced Drug Delivery Reviews*, vol. 58, no. 1, pp. 52–67, 2006.
- [11] S. Mitragotri, "Immunization without needles," *Nature Reviews Immunology*, vol. 5, no. 12, pp. 905–916, 2005.
- [12] L. C. Freytag and J. D. Clements, "Mucosal adjuvants," *Vaccine*, vol. 23, no. 15, pp. 1804–1813, 2005.

- [13] N. Olivera, M. Cédola, and R. Gómez, "The cholera toxin as a biotechnological tool," in *Cholera*, S. J. T. Gowder, Ed., pp. 129–152, InTech, Zagreb, Croatia, 2012.
- [14] W. Langridge, B. Dénes, and I. Fodor, "Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases," *Current Opinion in Investigational Drugs*, vol. 11, no. 8, pp. 919–928, 2010.
- [15] A. George-Chandy, K. Eriksson, M. Lebens, I. Nordström, E. Schön, and J. Holmgren, "Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells," *Infection and Immunity*, vol. 69, no. 9, pp. 5716–5725, 2001.
- [16] S.-M. Kang, Q. Yao, L. Guo, and R. W. Compans, "Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B," *Journal of Virology*, vol. 77, no. 18, pp. 9823–9830, 2003.
- [17] M. Lebens, J.-B. Sun, H. Sadeghi et al., "A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection," *Vaccine*, vol. 21, no. 5-6, pp. 514–520, 2003.
- [18] A. A. Ashkar, K. L. Mossman, B. K. Coombes, C. L. Gyles, and R. Mackenzie, "FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling," *PLoS Pathogens*, vol. 4, no. 12, Article ID e1000233, 2008.
- [19] K. L. Mossman, M. F. Mian, N. M. Lauzon et al., "Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand," *Journal of Immunology*, vol. 181, no. 10, pp. 6702–6706, 2008.
- [20] A. Robinson, A. R. Gorringe, S. G. P. Funnell, and M. Fernandez, "Serospecific protection of mice against intranasal infection with *Bordetella pertussis*," *Vaccine*, vol. 7, no. 4, pp. 321–324, 1989.
- [21] H. O. Hallander, M. Ljungman, M. Jahnmatz, J. Storsaeter, L. Nilsson, and L. Gustafsson, "Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection," *APMIS*, vol. 117, no. 9, pp. 660–671, 2009.
- [22] T. Kasuga, Y. Nakase, K. Ukishima, and K. Takatsu, "Studies on *Haemophilus pertussis*. V. Relation between the phase of bacilli and the progress of the whooping-cough," *The Kitasato Archives of Experimental Medicine*, vol. 27, no. 3, pp. 57–62, 1954.
- [23] T. Kasuga, Y. Nakase, K. Ukishima, and K. Takatsu, "Studies on *Haemophilus pertussis*. IV. Preventive potency of each phase organisms of *H. pertussis* in mice," *The Kitasato Archives of Experimental Medicine*, vol. 27, no. 3, pp. 49–55, 1954.
- [24] T. Kasuga, Y. Nakase, K. Ukishima, and K. Takatsu, "Studies on *Haemophilus pertussis*. III. Some properties of each phase of *H. pertussis*," *The Kitasato Archives of Experimental Medicine*, vol. 27, no. 3, pp. 37–47, 1954.
- [25] D. W. Stainer and M. J. Scholte, "A simple chemically defined medium for the production of phase I *Bordetella pertussis*," *Journal of General Microbiology*, vol. 63, no. 2, pp. 211–220, 1970.
- [26] A. Paula de Mattos Arêas, M. Leonor Sarno de Oliveira, C. Raul Romero Ramos, M. E. Sbrogio-Almeida, I. Raw, and P. L. Ho, "Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in *Escherichia coli*," *Protein Expression and Purification*, vol. 25, no. 3, pp. 481–487, 2002.
- [27] A. P. M. Arêas, M. L. S. Oliveira, E. N. Miyaji et al., "Expression and characterization of cholera toxin B-pneumococcal surface adhesin a fusion protein in *Escherichia coli*: ability of CTB-PsaA to induce humoral immune response in mice," *Biochemical and Biophysical Research Communications*, vol. 321, no. 1, pp. 192–196, 2004.
- [28] A. Habarta, P. A. E. Abreu, N. Olivera et al., "Increased immunogenicity to LipL32 of *Leptospira interrogans* when expressed as a fusion protein with the cholera toxin B subunit," *Current Microbiology*, vol. 62, no. 2, pp. 526–531, 2011.
- [29] M. E. Gaillard, D. Bottero, C. E. Castuma, L. A. Basile, and D. Hozbor, "Laboratory adaptation of *Bordetella pertussis* is associated with the loss of type three secretion system functionality," *Infection and Immunity*, vol. 79, no. 9, pp. 3677–3682, 2011.
- [30] D. Bottero, M. E. Gaillard, M. Fingerhann et al., "Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical *Bordetella pertussis* strains," *Clinical and Vaccine Immunology*, vol. 14, no. 11, pp. 1490–1498, 2007.
- [31] NIH, *Guide For the Care and Use of Laboratory Animals*, 1996.
- [32] J. Sánchez and J. Holmgren, "Cholera toxin structure, gene regulation and pathophysiological and immunological aspects," *Cellular and Molecular Life Sciences*, vol. 65, no. 9, pp. 1347–1360, 2008.
- [33] C. H. Wirsing von König, S. Halperin, M. Riffelmann, and N. Guiso, "Pertussis of adults and infants," *Lancet Infectious Diseases*, vol. 2, no. 12, pp. 744–750, 2002.
- [34] N. Mielcarek, A.-S. Debrie, D. Raze et al., "Attenuated *Bordetella pertussis*: new live vaccines for intranasal immunisation," *Vaccine*, vol. 24, supplement 2, pp. S54–S55, 2006.
- [35] N. Mielcarek, A.-S. Debrie, D. Raze et al., "Live attenuated *B. pertussis* as a single-dose nasal vaccine against whooping cough," *PLoS Pathogens*, vol. 2, no. 7, p. e65, 2006.
- [36] M. Roberts, I. Copley, S. Chatfield, and G. Dougan, "Protection of mice against respiratory *Bordetella pertussis* infection by intranasal immunization with P.69 and FHA," *Vaccine*, vol. 11, no. 8, pp. 866–872, 1993.
- [37] R. D. Shahin, D. F. Amsbaugh, and M. F. Leef, "Mucosal immunization with filamentous hemagglutinin protects against *Bordetella pertussis* respiratory infection," *Infection and Immunity*, vol. 60, no. 4, pp. 1482–1488, 1992.
- [38] L. Gustafsson, H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter, "A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine," *The New England Journal of Medicine*, vol. 334, pp. 349–355, 1996.
- [39] P. Olin, F. Rasmussen, L. Gustafsson, H. O. Hallander, and H. Heijbel, "Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines," *The Lancet*, vol. 350, pp. 1569–1577, 1997.
- [40] J. D. Cherry, J. Gornbein, U. Heininger, and K. Stehr, "A search for serologic correlates of immunity to *Bordetella pertussis* cough illnesses," *Vaccine*, vol. 16, no. 20, pp. 1901–1906, 1998.
- [41] J. Storsaeter, H. O. Hallander, L. Gustafsson, and P. Olin, "Levels of anti-pertussis antibodies related to protection after household exposure to *Bordetella pertussis*," *Vaccine*, vol. 16, no. 20, pp. 1907–1916, 1998.
- [42] Y. Xu, Y. Wang, Y. Tan et al., "Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from *Bordetella pertussis*," *BMC microbiology*, vol. 9, p. 274, 2009.
- [43] M. Isaka, Y. Yasuda, T. Taniguchi et al., "Mucosal and systemic antibody responses against an acellular pertussis vaccine

- in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant," *Vaccine*, vol. 21, no. 11-12, pp. 1165–1173, 2003.
- [44] S. F. Lee, S. A. Halperin, D. F. Salloum, A. MacMillan, and A. Morris, "Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein," *Infection and Immunity*, vol. 71, no. 4, pp. 2272–2275, 2003.
- [45] J. Holmgren, J. Adamsson, F. Anjuère et al., "Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA," *Immunology Letters*, vol. 97, no. 2, pp. 181–188, 2005.
- [46] J. Sánchez and J. Holmgren, "Cholera toxin—a foe & a friend," *Indian Journal of Medical Research*, vol. 133, no. 2, pp. 153–163, 2011.
- [47] T. Harakuni, H. Sugawa, A. Komesu, M. Tadano, and T. Arakawa, "Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems," *Infection and Immunity*, vol. 73, no. 9, pp. 5654–5665, 2005.
- [48] S. M. M. Hellwig, A. B. van Spruiel, J. F. P. Schellekens, F. R. Mooi, and J. G. J. van de Winkel, "Immunoglobulin A-mediated protection against *Bordetella pertussis* infection," *Infection and Immunity*, vol. 69, no. 8, pp. 4846–4850, 2001.
- [49] C. Hervouet, C. Luci, N. Çuburu et al., "Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract," *Vaccine*, vol. 28, no. 34, pp. 5582–5590, 2010.
- [50] F. C. Pimenta, E. N. Miyaji, A. P. M. Arêas et al., "Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with *Streptococcus pneumoniae* and has negligible impact on the nasopharyngeal and oral microbiota of mice," *Infection and Immunity*, vol. 74, no. 8, pp. 4939–4944, 2006.
- [51] G. A. Price and R. K. Holmes, "Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera," *PLoS ONE*, vol. 7, Article ID e42434, 2012.
- [52] A. K. Gloude-mans, M. Plantinga, M. Williams et al., "The mucosal adjuvant cholera toxin B instructs non-mucosal dendritic cells to promote IgA production via retinoic acid and TGF- $\beta$ ," *PLoS ONE*, vol. 8, Article ID e59822, 2013.
- [53] J. Holmgren, C. Czerkinsky, K. Eriksson, and A. Mharandi, "Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges," *Vaccine*, vol. 21, supplement 2, pp. S89–S95, 2003.
- [54] K. A. Skelding, D. K. Hickey, J. C. Horvat et al., "Comparison of intranasal and transcutaneous immunization for induction of protective immunity against *Chlamydia muridarum* respiratory tract infection," *Vaccine*, vol. 24, no. 3, pp. 355–366, 2006.
- [55] R. J. Salmond, J. A. Luross, and N. A. Williams, "Immune modulation by the cholera-like enterotoxins," *Expert Reviews in Molecular Medicine*, vol. 4, pp. 1–16, 2002.
- [56] P.-H. Kim, L. Eckmann, W. J. Lee, W. Han, and M. F. Kagnoff, "Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF- $\beta$ 1," *Journal of Immunology*, vol. 160, no. 3, pp. 1198–1203, 1998.
- [57] R. J. Vandebriel, E. R. Gremmer, J. P. Vermeulen et al., "Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with *Bordetella pertussis*," *Vaccine*, vol. 25, no. 12, pp. 2346–2360, 2007.
- [58] C. Fromantin, B. Jamot, J. Cohen, L. Piroth, P. Pothier, and E. Kohli, "Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and *Escherichia coli* heat-labile toxin, induce a Th1/Th2-like immune response," *Journal of Virology*, vol. 75, no. 22, pp. 11010–11016, 2001.
- [59] K. Imaoka, C. J. Miller, M. Kubota et al., "Nasal immunization of nonhuman primates with simian immunodeficiency virus p55(gag) and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues," *Journal of Immunology*, vol. 161, no. 11, pp. 5952–5958, 1998.
- [60] P. J. Ross, C. E. Sutton, S. Higgins et al., "Relative contribution of Th1 and Th17 cells in adaptive immunity to *Bordetella pertussis*: towards the rational design of an improved acellular pertussis vaccine," *PLoS Pathogens*, vol. 9, Article ID e1003264, 2013.
- [61] F. W. van Ginkel, R. J. Jackson, Y. Yuki, and J. R. McGhee, "Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues," *Journal of Immunology*, vol. 165, no. 9, pp. 4778–4782, 2000.
- [62] M. Mutsch, W. Zhou, P. Rhodes et al., "Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland," *The New England Journal of Medicine*, vol. 350, no. 9, pp. 896–903, 2004.
- [63] H.-J. Cho, J.-Y. Kim, Y. Lee et al., "Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants," *Vaccine*, vol. 28, no. 14, pp. 2598–2606, 2010.